Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15081962 | 0.85 | OPRL1 (0.48) | KMT2AALDH1A1MEN1POLBTSHR | |
| SCHEMBL807570 | 0.84 | ALDH1A1 (0.47) | KMT2AALDH1A1MEN1POLBTSHR | |
| SCHEMBL12073915 | 0.84 | HDAC8 (0.51) | HTR7KMT2AMEN1LMNAHTT | |
| SCHEMBL15084330 | 0.82 | LMNA (0.55) | HTR7KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL15084325 | 0.73 | TSHR (0.50) | HTR7KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL14032661 | 0.73 | ALDH1A1 (0.72) | HTR7KMT2AALDH1A1MEN1CYP3A4 | |
| SCHEMBL15084316 | 0.72 | TSHR (0.71) | HTR7KMT2AMEN1HRH3TSHR | |
| SCHEMBL12301581 | 0.72 | CREBBP (0.52) | KMT2AALDH1A1MEN1HTTNPSR1 | |
| SCHEMBL10869575 | 0.72 | MPO (0.59) | ALDH1A1HRH3CYP3A4CYP2C19TSHR | |
| SCHEMBL12479944 | 0.70 | CFD (0.60) | KMT2AALDH1A1POLBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | HTR7 3609/4885KMT2A 3379/4885ALDH1A1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.